NOW IS THE TIME:
REALIZE THE IMPACT OF TYSABRI
Significant reduction in the risk of increased physical disability sustained for 12 weeks1
The primary endpoint at 2 years was time to onset of sustained increase in disability, defined as an increase of ≥1.0 point on the EDSS from baseline EDSS ≥1.0 that was sustained for 12 weeks, or ≥1.5-point increase on the EDSS from baseline EDSS=0 that was sustained for 12 weeks.
Increase excluded disability confirmation within 30 days of a relapse.2
Potential Risk of TYSABRI and PML
- TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability
- Cases of PML have been reported in patients taking TYSABRI who were recently or concomitantly treated with immunomodulators or immunosuppressants, as well as in patients receiving TYSABRI as monotherapy
- Because of the risk of PML, TYSABRI is available only through a special restricted distribution program called the TOUCH® Prescribing Program
- Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML
Significant and powerful reduction in annualized relapse rate at 2 years
Results of AFFIRM (NAtalizumab Safety and EFFIcacy in Relapsing-Remitting MS), a 2-year, global, multicenter, double-blind, parallel-group trial that randomized 942 patients (in a 2:1 ratio) to receive either TYSABRI monotherapy (300 mg by intravenous infusion [n=627]) or placebo (n=315) every 4 weeks for up to 28 months (30 infusions).1
Significant reduction in Gd+ lesions at 2 years1
- Changes in MRI findings often do not correlate with changes in the clinical status of patients (e.g., disability progression). The prognostic significance of these MRI findings has not been evaluated
- 97% of TYSABRI patients were free of Gd+ lesions at 2 years vs 72% of placebo patients (p<0.001)
- 57% of TYSABRI patients were free of new or enlarging T2 hyperintense lesions vs 15% of placebo patients (p<0.001)
- Polman CH, O'Connor PW, Havrdova E, et al; for the AFFIRM Investigators. A randomized, placebo–controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
- Data on file, Biogen Idec.